EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Effect of a combination therapy between IL-12 and soluble IL-4 receptor (sIL-4R) on Candida albicans and herpes simplex virus type I infections in thermally injured mice



Effect of a combination therapy between IL-12 and soluble IL-4 receptor (sIL-4R) on Candida albicans and herpes simplex virus type I infections in thermally injured mice



Canadian Journal of Microbiology 48(10): 886-894



The effectiveness of a combination using IL-12 and soluble IL-4 receptor (sIL-4R) to treat severe infections of herpes simplex virus type 1 (HSV-1) and Candida albicans in thermally injured mice was investigated. Although sIL-4R decreased burn-associated type 2 T-cell responses, the effect of sIL-4R was minimal on the morbidity and mortality of thermally injured mice exposed to 250 times LD50 of HSV-1 or 10 times LD50 of C. albicans. Compared with 100% mortality in control mice, mortality for HSV-1 and C. albicans was 40 and 20%, respectively, in thermally injured mice that received IL-12 and sIL-4R in combination. After stimulation with anti-CD3 monoclonal antibody, splenic T cells from thermally injured mice exposed to large amounts of HSV-1 or C. albicans did not produce gamma interferon (IFN-gamma) into their culture fluids. However, IFN-gamma was produced by splenic T cells from thermally injured and infected mice treated with IL-12 and sIL-4R in combination. These results suggest that therapeutic treatment with a combination of IL-12 and sIL-4R may be effective by inducing type 1 T-cell responses in thermally injured mice exposed to large amounts of HSV-1 or C. albicans.

(PDF same-day service: $19.90)

Accession: 017870403

Download citation: RISBibTeXText

PMID: 12489778

DOI: 10.1139/w02-085



Related references

The regulation of burn-associated infections with herpes simplex virus type 1 or Candida albicans by a non-toxic aconitine-hydrolysate, benzoylmesaconine. Part 1: Antiviral and anti-fungal activities in thermally injured mice. Immunology and Cell Biology 76(3): 202-208, 1998

Therapeutic protective effects of IL-12 combined with soluble IL-4 receptor against established infections of herpes simplex virus type 1 in thermally injured mice. Journal of Immunology 162(12): 7148-7154, 1999

Effect of IL-12 combined with soluble IL-4 receptor in thermally injured mice exposed to large amounts of herpes simplex virus type 1. FASEB Journal 12(5): A1069, March 20, 1998

IL-12 combined with soluble IL-4 receptor protects thermally injured mice-infected with herpes simplex virus type 1. Cytokine 9(11): 906, 1997

Effect of growth hormone on the herpes simplex virus type 1 infection in the thermally injured mice. Abstracts of the General Meeting of the American Society for Microbiology 97(0): 243, 1997

Effect of IL-12 on the susceptibility of thermally injured mice to the opportunistic infection of herpes simplex virus type 1. FASEB Journal 8(4-5): A995, 1994

Interleukin-12 protects thermally injured mice from herpes simplex virus type 1 infection. Journal of Leukocyte Biology 59(5): 623-630, 1996

Benzoylmesaconine improves resistance of thermally injured mice to the infection of herpes simplex virus type 1. FASEB Journal 8(4-5): A488, 1994

Glycyrrhizin protects thermally injured mice infected with Herpes simplex virus type 1 through the modulation of IL-12 unresponsiveness. Journal of Antimicrobial Chemotherapy 44(SUPPL A): 41, July, 1999

Growth hormone improves the resistance of thermally injured mice infected with herpes simplex virus type 1. Journal of Trauma 44(3): 517-522, 1998

Vaccinia virus recombinant that expresses the herpes simplex virus type 1 glycoprotein d gene protects mice against lethal challenge by herpes simplex virus type 1 or herpes simplex type 2 and the establishment of a latent ganglionic infection by herpes simplex virus type 1. Lerner, R A , R M Chanock And F Brown (Ed ) Vaccines 85: Molecular And Chemical Basis Of Resistance to Parasitic, Bacterial, And Viral Diseases; Meeting, 1983 Xxi+407p Cold Spring Harbor Laboratory: Cold Spring Harbor, N Y , Usa Illus Paper 169-174, 1985

A combination therapy using IL-12 and soluble IL-4 receptor on herpes simplex virus type 1 infection in a human-SCID chimera model of thermal injury. Clinical Immunology (Orlando) 105(3): 363-370, December, 2002